S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan

DaVita (DVA) Competitors

$126.92
-0.05 (-0.04%)
(As of 03/1/2024 ET)

DVA vs. FMS, SHC, PGNY, UHS, TECH, RGEN, PODD, UTHR, TFX, and CTLT

Should you be buying DaVita stock or one of its competitors? The main competitors of DaVita include Fresenius Medical Care (FMS), Sotera Health (SHC), Progyny (PGNY), Universal Health Services (UHS), Bio-Techne (TECH), Repligen (RGEN), Insulet (PODD), United Therapeutics (UTHR), Teleflex (TFX), and Catalent (CTLT). These companies are all part of the "medical" sector.

DaVita vs.

DaVita (NYSE:DVA) and Fresenius Medical Care (NYSE:FMS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.

DaVita has higher earnings, but lower revenue than Fresenius Medical Care. DaVita is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$12.14B0.92$691.53M$7.4017.15
Fresenius Medical Care$21.05B0.54$540.07M$0.9221.04

DaVita has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Fresenius Medical Care has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

DaVita has a net margin of 5.70% compared to Fresenius Medical Care's net margin of 2.56%. DaVita's return on equity of 64.42% beat Fresenius Medical Care's return on equity.

Company Net Margins Return on Equity Return on Assets
DaVita5.70% 64.42% 4.63%
Fresenius Medical Care 2.56%4.99%2.15%

DaVita currently has a consensus target price of $115.60, indicating a potential downside of 8.92%. Fresenius Medical Care has a consensus target price of $24.00, indicating a potential upside of 23.97%. Given Fresenius Medical Care's higher possible upside, analysts clearly believe Fresenius Medical Care is more favorable than DaVita.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DaVita
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Fresenius Medical Care
1 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.11

In the previous week, DaVita had 14 more articles in the media than Fresenius Medical Care. MarketBeat recorded 16 mentions for DaVita and 2 mentions for Fresenius Medical Care. Fresenius Medical Care's average media sentiment score of 1.46 beat DaVita's score of 0.56 indicating that Fresenius Medical Care is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DaVita
4 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fresenius Medical Care
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

84.7% of DaVita shares are owned by institutional investors. Comparatively, 5.8% of Fresenius Medical Care shares are owned by institutional investors. 1.4% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DaVita received 88 more outperform votes than Fresenius Medical Care when rated by MarketBeat users. Likewise, 61.74% of users gave DaVita an outperform vote while only 53.75% of users gave Fresenius Medical Care an outperform vote.

CompanyUnderperformOutperform
DaVitaOutperform Votes
489
61.74%
Underperform Votes
303
38.26%
Fresenius Medical CareOutperform Votes
401
53.75%
Underperform Votes
345
46.25%

Summary

DaVita beats Fresenius Medical Care on 13 of the 18 factors compared between the two stocks.


Get DaVita News Delivered to You Automatically

Sign up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DVA vs. The Competition

MetricDaVitahealth & allied services, not elsewhere classified IndustryMedical SectorNYSE Exchange
Market Cap$11.13B$2.21B$5.09B$17.54B
Dividend YieldN/A2.16%2.82%3.57%
P/E Ratio17.1523.95221.9123.52
Price / Sales0.9233.393,097.177.19
Price / Cash7.5514.9599.9215.94
Price / Book8.943.504.535.86
Net Income$691.53M$60.00M$114.85M$863.03M
7 Day Performance1.33%-1.33%5.73%1.63%
1 Month Performance14.13%-2.62%12.81%3.14%
1 Year Performance54.76%-14.08%12.92%94.49%

DaVita Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FMS
Fresenius Medical Care
4.4793 of 5 stars
$19.62
-0.4%
$24.00
+22.3%
+2.2%$11.51B$21.05B21.331,358Short Interest ↓
SHC
Sotera Health
2.0124 of 5 stars
$17.34
+1.6%
$20.00
+15.3%
-16.4%$4.90B$1.00B-15.763,000Earnings Report
Analyst Upgrade
News Coverage
High Trading Volume
PGNY
Progyny
4.3738 of 5 stars
$40.79
+2.3%
$48.60
+19.1%
-0.6%$3.91B$1.03B78.44393Earnings Report
Analyst Report
Analyst Revision
News Coverage
UHS
Universal Health Services
4.6694 of 5 stars
$165.79
+0.9%
$159.07
-4.1%
+34.2%$11.32B$13.40B17.4093,800Earnings Report
Analyst Report
Analyst Revision
News Coverage
TECH
Bio-Techne
4.9077 of 5 stars
$73.21
+1.8%
$84.11
+14.9%
-4.1%$11.51B$1.14B53.053,050Short Interest ↑
Positive News
RGEN
Repligen
3.6807 of 5 stars
$192.71
+0.5%
$196.70
+2.1%
+8.3%$10.75B$638.76M267.661,783Insider Selling
PODD
Insulet
4.9759 of 5 stars
$166.62
-1.3%
$250.33
+50.2%
-40.2%$11.64B$1.70B57.262,600Insider Selling
High Trading Volume
UTHR
United Therapeutics
4.9767 of 5 stars
$226.75
+1.4%
$292.80
+29.1%
-5.2%$10.67B$2.33B11.431,168Positive News
TFX
Teleflex
4.8657 of 5 stars
$226.04
-0.8%
$265.56
+17.5%
-5.4%$10.62B$2.97B30.0215,500Analyst Revision
CTLT
Catalent
3.6957 of 5 stars
$58.24
-0.1%
$52.46
-9.9%
-19.7%$10.53B$4.28B-8.5617,800Analyst Report
Short Interest ↓

Related Companies and Tools

This page (NYSE:DVA) was last updated on 3/3/2024 by MarketBeat.com Staff